Compare Hims and Hers Health Inc (HIMS) vs SMX Security Matters plc (SMX) Price & Performance

Hims & Hers Health trades at $30.92, up 4.67% on the day, amid a bearish technical signal and significant legal headwinds from multiple securities class action lawsuits. The stock shows mixed fundamentals with strong revenue growth to $2.35 billion in 2025 but a sharp reversal to a net loss of -$142 million in 2026, reflecting profitability challenges. Valuation ratios appear elevated with a P/E of 57.14 and EV/EBITDA of 205.86, while analyst consensus remains cautiously optimistic with a $32.17 price target.

The outlook is clouded by legal risks and recent earnings misses, though the company's gross margin of 68.43% indicates underlying business strength. Investment opportunity hinges on resolving regulatory scrutiny and returning to profitability, but near-term volatility is likely. Key risks include the FTC lawsuit outcome and sustained negative cash flow, demanding careful risk assessment by investors.

SMX trades at $3.80, down 2.56% with a bearish technical outlook despite oversold RSI readings. The company shows severe financial distress with no revenue, negative EBITDA of -$130.44M, and deeply negative ROE of -819.22%. Recent news highlights SMX's digital material passport technology gaining media attention from Forbes, TIME, and Boston Herald in September-October 2026, focusing on recycled plastic verification and circular economy applications.

The stock faces substantial fundamental challenges with no current revenue generation and significant operating losses. While media coverage suggests technological potential in material verification, the absence of revenue and massive negative profitability metrics present extreme risk. Investment viability depends entirely on SMX's ability to monetize its technology platform amid ongoing cash burn.